P5451Catestatin and chronic heart failure patients with an acute decompensation event: clinical characteristics and 30-day all-cause mortality

Abstract Background Catestatin (CST) is a cardiovascular regulator with pleiotropic systemic functions that might affect the course of acutely decompensated heart failure (ADHF). Purpose To determine the association of serum CST with the 30-day all-cause mortality and to compare clinical and laboratory parameters between ADHF patients within the lowest vs. highest quartile of CST concentration. Methods Eighty-two consecutive ADHF patients, as adjudicated per ESC 2016 HF criteria, were enrolled in the study during 2018–2019. Results Mean age of the enrolled cohort was 70.8±9.3 years and 54.9% were women. Seventy percent of patients were in NYHA III functional class and nearly half had a reduced LVEF. Median CST value was 5.6 ng/mL (IQR 3, 12). During the 30-day follow-up, ten patients died (12.2%) due to all causes. CST levels were significantly higher among patients that died compared to survivors (21.9±6.3 vs. 10.2±1.5 ng/mL, p=0.0139, respectively). Patients in the highest CST quartile had higher mortality and disease burden accompanied by more prominent laboratory abnormalities, compared to patients in the lowest CST quartile. Compared groups did not significantly differ in terms of dosages and type of baseline HF pharmacotherapy. Table 1. Clinical characteristics Variable Lowest CST quartile (12 ng/mL) p-value Age, years 72.8±8.3 70.0±7.9 0.281 Women, % 45.0 60.0 0.342 LVEF, biplane Simpson, % 39.0 41.0 0.645 30-day all-cause mortality, % 0.0 20.0 0.035 Mean NYHA functional class 2.83±0.38 3.21±0.42 0.007 Mean CKD stage, CKD-EPI 2.37±0.83 3.06±0.99 0.029 Mean arterial pressure, mmHg 99.7±17.8 100.1±19.2 0.953 NT-proBNP, pmol/L 535.3±522.4 1550.0±992.2 0.040 C-reactive protein, mg/L 9.37±7.47 32.90±18.35 0.015 High-sensitivity cardiac Troponin I, ng/L 20.60±18.05 30.02±27.38 0.256 Creatinine, μmol/L 102.9±38.9 150.6±91.2 0.038 Urea, mmol/L 9.6±3.5 14.3±7.1 0.012 Neutrophil-to-lymphocyte ratio 3.6±1.9 5.4±3.1 0.045 Hemoglobin, g/L 137.3±17.4 124.6±18.8 0.038 Figure 1. CST and 30-day mortality Conclusions Higher levels of catestatin measured during the hospitalization event among ADHF patients are associated with 30-day all-cause mortality and worse in-hospital profile thus might facilitate short-term prognosis. Acknowledgement/Funding None